ArticleFrontiers in oncology2025
Hotspots and frontiers of the relationship between gastric cancer and cancer-associated fibroblasts: a bibliometric analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics investigation of benzo[a]pyrene in gastric cancer: comprehensive network toxicology, machine learning and molecular docking approaches.Molecular diversity · 2026Article
- Immune snapshots along the inflammation-to-cancer road in bladder urothelium.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer-Associated Fibroblasts (CAFs) are pivotal stromal constituents within the Tumor Microenvironment (TME), characterized by marked heterogeneity and plasticity. Over the past two decades, a notable association between Gastric Cancer (GC) and CAFs has been established. Despite this, there remains a paucity of comprehensive data to guide researchers in understanding the prevalence and potential research trajectories concerning GC and CAFs. Methods: This study conducted an extensive literature search within the Web of Science Core Collection database from January 1, 2003, to December 31, 2023. Bibliometric analysis and visualization were performed using VOSviewer, CiteSpace, R software, and Microsoft Excel. Results: A total of 1170 articles were included. These articles were disseminated across 200 journals and incorporated 1800 distinct keywords. A notable surge in publications has been observed from 2011 to 2023. China emerged as the leading contributor to both article count and citations. Prominent research institutions in this domain include Osaka City University, Shanghai Jiaotong University, and National Cancer Research Center Hospital. Notable researchers, such as Masakazu Yashiro and Kosei Hirakawa from Osaka City University and Zhenggang Zhu from Shanghai Jiaotong University, were among the most productive and highly cited authors. FRONTIERS IN ONCOLOGY boasts the highest number of publications, whereas ONCOGENE ranks as the most cited journal. The primary research foci within the realm of CAFs and GC encompass the impact of CAFs on GC cell proliferation, angiogenesis, invasion, metastasis, epithelial-mesenchymal transition, immunosuppression, drug resistance, and the interplay between CAFs and GC. Conclusion: Using bibliometric analysis, this study presents a panoramic view of the research landscape of CAFs and GC from 2003 to 2023. It highlights prominent research areas and anticipates future directions with the aim of offering valuable insights and strategic recommendations for future endeavors in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.